



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et. al. Examiner: Dr. K. C. Carlson
Serial No.: 08/087,132 Art Unit: 1812
Filed: July 2, 1993 Docket: IG4-9.2(FWC)

For: NEW DIAGNOSTIC AND TREATMENT METHODS
INVOLVING THE CYSTIC FIBROSIS TRANSMEMBRANE
REGULATOR

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

--CERTIFICATE OF MAILING UNDER 37 CFR §§ 1.8--

SIR:

I hereby certify that the attached correspondence entitled "Change in Correspondence Address" is being deposited this day with the U.S. Postal Service as first class mail, sufficient postage prepaid, in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

By: Kim Akeeli
Kim Akeeli

Dated: July 25, 1995

/
/
/
/
/
/
/
/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et. al. Examiner: Dr. K. C. Carlson
Serial No.: 08/087,132 Art Unit: 1812
Filed: July 2, 1993 Docket: IG4-9.2(FWC)

For: NEW DIAGNOSTIC AND TREATMENT METHODS
INVOLVING THE CYSTIC FIBROSIS TRANSMEMBRANE
REGULATOR

BOX AF,

Honorable Commissioner of Patents and Trademarks,
Washington, DC 20231

Payment of Fee for Transitional After Final Practice
under 37 CFR 1.129(a) and 37 CFR 1.17(r)

SIR:

Applicants hereby request **withdrawl of the final rejection** that is pending herein under 37 CFR 1.129(a) "Transitional After Final Practice."

Pursuant to 37 CFR 1.17(r) the Patent Office is hereby authorized to charge the **transitional fee** of \$750.00 to Deposit Account **07- 1074**.


No extension fee is due in connection with the Reply with Amendment submitted herewith since it is being filed within the three months of the mailing of the Final Action that is pending herein. However, should the Patent Office determine that any other fee is necessary for acceptance of this paper, or for the claims presented herein, then the Patent Office is authorized to charge such fee to Deposit Account **07- 1074**.

A duplicate of this Paper is enclosed.

08/087,132
January 16, 1996
page 2

Respectfully submitted,

GENZYME CORPORATION

By: 
Mark A. Hofer, Esquire
Registration No. 30,068
Attorney for Applicants

Dated: January 16, 1996

One Mountain Road
Framingham, MA 01701- 9322
(508) 872-8400 x 2555

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Gregory et al.	Examiner:	Dr. K. C. Carlson
Serial No:	08/087,132	Art Unit:	1812
Filed:	July 2, 1993	Docket:	IG 4-9.2(FWC)
Title:	New Diagnostic and Treatment Methods Involving the Cystic Fibrosis Transmembrane Regulator		

The Honorable Commissioner of Patent and Trademarks
Washington, DC 20231

Dear Sir:

Transmitted herewith is an AMENDMENT in the above identified application.

1. The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUS PAID FOR	NUMBER OF EXTRA	RATE/LARGE ENTITY	FEE
TOTAL	37	MINUS	133	= 0	x 22	\$ 0
INDEP	6	MINUS	13	= 0	x 76	\$ 0
MULTIPLE DEPENDENT CLAIMS					x 240	0
TOTAL ADDITIONAL FEES						\$ 0

NO NEW MULTIPLE DEPENDENT CLAIMS ARE BEING ADDED

TOTAL \$ 0

2. The Commissioner is hereby authorized and requested to charge \$ 0 for the presentation of extra claims under 37 C.F.R. 1.16 and all patent processing fees under 37 C.F.R. 1.17, along with any additional fees under 37 C.F.R. 1.16 and 1.17, which may be required, or credit any overpayment, associated with this communication to Deposit Account No. 07-1074. A duplicate of this document is enclosed for this purpose.
3. Since the number of independent claims and the number of total claims that are now pending herein are substantially less than the numbers thereof that have been previously paid for, no fee is due in connection with this supplementary submission. However, the Patent Office is authorized to charge any fee that it determines is necessary in order to secure the filing of this Supplementary Reply and all enclosures.

Respectfully submitted,
GENZYME CORPORATION



Elizabeth Lassen, Esquire
Reg. No. 31,845
Attorney for Applicants

17

Dated: January 16, 1996